[ CAS No. 57295-30-4 ] {[proInfo.proName]}

Name: 57295-30-4|3-Hydroxy-4-methylbenzaldehyde|97%
Brand: Ambeed
SKU: A548351
Price: 18.0 USD
Availability: InStock
Rating: 90 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 57295-30-4

Structure of 57295-30-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 57295-30-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 57295-30-4 ]

SDS Specification

Alternatived Products of [ 57295-30-4 ]

Product Details of [ 57295-30-4 ]

CAS No. :	57295-30-4	MDL No. :	MFCD01632496
Formula :	C₈H₈O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DHVJHJQBQKKPNB-UHFFFAOYSA-N
M.W :	136.15	Pubchem ID :	585182
Synonyms :

Calculated chemistry of [ 57295-30-4 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.12
Num. rotatable bonds :	1
Num. H-bond acceptors :	2.0
Num. H-bond donors :	1.0
Molar Refractivity :	38.82
TPSA :	37.3 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.09 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.25
Log Po/w (XLOGP3) :	1.46
Log Po/w (WLOGP) :	1.51
Log Po/w (MLOGP) :	1.12
Log Po/w (SILICOS-IT) :	1.96
Consensus Log Po/w :	1.46

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.98
Solubility :	1.42 mg/ml ; 0.0104 mol/l
Class :	Very soluble
Log S (Ali) :	-1.85
Solubility :	1.93 mg/ml ; 0.0141 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.13
Solubility :	1.02 mg/ml ; 0.00746 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.0

Safety of [ 57295-30-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 57295-30-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 57295-30-4 ]
Downstream synthetic route of [ 57295-30-4 ]

[ 57295-30-4 ] Synthesis Path-Upstream 1~10

1
[ 90953-62-1 ]
[ 57295-30-4 ]

Yield	Reaction Conditions	Operation in experiment
11%	With manganese(IV) oxide In tetrahydrofuran at 20 - 50℃; for 6 h;	To a solution of the product step (i) (440.0 mg, 3.18 mmol) in THF (4.4 mL) MnO₂(552.9 mg, 6.36 mmol) was added at rt. After stirring for 6 h at 50° C., the mixture was filtered through the celite pad. The filtrate was concentrated, and the residue was purified by flash column chromatography to give the title compound (46.1 mg, 11percent) as a pale yellow solid.¹H NMR δ (CDCl₃) 9.90 (1H, s), 7.36 (1H, dd, J=7.76, 1.44 Hz), 7.30 (1H, s), 7.29 (1H, d, J=5.52 Hz), 5.33 (1H, s), 2.33 (3H, s).

Reference： [1] Patent: US2011/136801, 2011, A1, . Location in patent: Page/Page column 44

2
[ 50-00-0 ]
[ 90953-62-1 ]
[ 154550-07-9 ]
[ 57295-30-4 ]

Reference： [1] Synthetic Communications, 2005, vol. 35, # 22, p. 2869 - 2874

3
[ 586-30-1 ]
[ 57295-30-4 ]

Reference： [1] Synthetic Communications, 2005, vol. 35, # 22, p. 2869 - 2874
[2] Patent: US2011/136801, 2011, A1,

4
[ 7577-74-4 ]
[ 57295-30-4 ]

Reference： [1] Monatshefte fuer Chemie, 1963, vol. 94, p. 1262 - 1270

5
[ 31680-07-6 ]
[ 57295-30-4 ]

Reference： [1] Journal of the Chemical Society, 1923, vol. 123, p. 2819,2823
[2] Liebigs Annalen der Chemie, 1985, vol. 1985, # 7, p. 1413 - 1421

6
[ 7218-22-6 ]
[ 57295-30-4 ]

Reference： [1] Monatshefte fuer Chemie, 1964, vol. 95, p. 129 - 146

7
[ 92203-12-8 ]
[ 57295-30-4 ]

Reference： [1] Monatshefte fuer Chemie, 1963, vol. 94, p. 1262 - 1270

8
[ 57295-30-4 ]
[ 74-88-4 ]
[ 24973-22-6 ]

Yield	Reaction Conditions	Operation in experiment
91%	Stage #1: With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 0.5 h; Stage #2: at 20℃;	General procedure: To a solution of the hydroxy-methylbenzaldehyde (34 mg,0.25 mmol) in anhydrous DMF (6.0 mL), K2CO3 (35 mg,0.25 mmol) was added and the mixture was stirred at room temperaturefor 30 minutes. Then, methyl iodide (30 μL, 68 mg,0.5 mmol) was added and the reaction was stirred at room temperatureovernight. The reaction was quenched by the additionof distilled water, and the aqueous phase was extracted threetimes with ethyl acetate. The combined organic phases weredried with MgSO4 and concentrated in vacuo. The residue waspurified by column chromatography on silica gel.

Reference： [1] Journal fuer Praktische Chemie/Chemiker-Zeitung, 1994, vol. 336, # 3, p. 255 - 259
[2] Beilstein Journal of Organic Chemistry, 2018, vol. 14, p. 734 - 746

9
[ 57295-30-4 ]
[ 77-78-1 ]
[ 24973-22-6 ]

Reference： [1] Liebigs Annalen der Chemie, 1985, vol. 1985, # 7, p. 1413 - 1421
[2] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1980, p. 1607 - 1613

10
[ 57295-30-4 ]
[ 64829-31-8 ]

Reference： [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1980, p. 1607 - 1613

[ 57295-30-4 ] Synthesis Path-Downstream 1~77

1
[ 31680-07-6 ]
[ 57295-30-4 ]

Reference： [1]Journal of the Chemical Society,1923,vol. 123,p. 2819,2823
[2]Liebigs Annalen der Chemie,1985,vol. 1985,p. 1413 - 1421

2
[ 92203-12-8 ]
[ 57295-30-4 ]

Reference： [1]Monatshefte fur Chemie,1963,vol. 94,p. 1262 - 1270

3
[ 4292-19-7 ]
[ 57295-30-4 ]
[ 157143-21-0 ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

4
[ 544-77-4 ]
[ 57295-30-4 ]
[ 157143-22-1 ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

5
[ 57295-30-4 ]
[ 98-88-4 ]
3-Benzoyloxy-4-methylbenzaldehyd [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

6
[ 57295-30-4 ]
[ 75-03-6 ]
[ 157143-20-9 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide;	The title compound was prepared by reaction of commercially available <strong>[57295-30-4]3-hydroxy-4-methyl-benzaldehyde</strong> with ethyl iodide in DMF using K2CO3 as base in analogy to the procedure described in M. J. Ashton, D. C. Cook, G. Fenton, J.-A. Karlsson, M. N. Palfreyman, D. Raeburn, A. J. Ratcliffe, J. E. Souness, S. Thurairatnam and N. Vicker J. Med. Chem. 1994, 37, 1696-1703.
	With potassium carbonate; In N,N-dimethyl-formamide;	Intermediate DlO; 3-Ethoxy-4-methyl-benzaldehvde [CAS RN 157143-20-9]; <n="82"/>The title compound was prepared by reaction of commercially available 3-hydroxy- 4-methyl-benzaldehyde with ethyl iodide in DMF using K2CO3 as base in analogy to the procedure described in M. J. Ashton, D. C. Cook, G. Fenton, J. -A. Karlsson, M. N. Palfreyman, D. Raeburn, A. J. Ratcliffe, J. E. Souness, S. Thurairatnam and N. Vicker /. Med. Chem. 1994, 37, 1696-1703.
	With potassium carbonate; In N,N-dimethyl-formamide;	3-Ethoxy-4-methyl-benzaldehyde [CAS RN 157143-20-9] The title compound was prepared by reaction of commercially available <strong>[57295-30-4]3-hydroxy-4-methyl-benzaldehyde</strong> with ethyl iodide in DMF using K2CO3 as base in analogy to the procedure described in M. J. Ashton, D. C. Cook, G. Fenton, J.-A. Karlsson, M. N. Palfreyman, D. Raeburn, A. J. Ratcliffe, J. E. Souness, S. Thurairatnam and N. Vicker J. Med. Chem. 1994, 37, 1696-1703.

With potassium carbonate; In N,N-dimethyl-formamide;

The title compound was prepared by reaction of commercially available [57295-30-4]3-hydroxy-4-methyl-benzaldehyde with ethyl iodide in DMF using K2CO3 as base in analogy to the procedure described in M. J. Ashton, D. C. Cook, G. Fenton, J.-A. Karlsson, M. N. Palfreyman, D. Raeburn, A. J. Ratcliffe, J. E. Souness, S. Thurairatnam and N. Vicker J. Med. Chem. 1994, 37, 1696-1703.

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259
[2]Patent: US2007/225271,2007,A1 .Location in patent: Page/Page column 42
[3]Patent: WO2008/692,2008,A2 .Location in patent: Page/Page column 80-81
[4]Patent: US2008/64697,2008,A1 .Location in patent: Page/Page column 34
[5]Patent: US2008/249101,2008,A1 .Location in patent: Page/Page column 29

7
[ 57295-30-4 ]
[ 638-45-9 ]
[ 138001-94-2 ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

8
[ 57295-30-4 ]
[ 77-78-1 ]
[ 24973-22-6 ]

Reference： [1]Liebigs Annalen der Chemie,1985,vol. 1985,p. 1413 - 1421
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

9
[ 57295-30-4 ]
[ 74-88-4 ]
[ 24973-22-6 ]

Yield	Reaction Conditions	Operation in experiment
91%		General procedure: To a solution of the hydroxy-methylbenzaldehyde (34 mg,0.25 mmol) in anhydrous DMF (6.0 mL), K2CO3 (35 mg,0.25 mmol) was added and the mixture was stirred at room temperaturefor 30 minutes. Then, methyl iodide (30 muL, 68 mg,0.5 mmol) was added and the reaction was stirred at room temperatureovernight. The reaction was quenched by the additionof distilled water, and the aqueous phase was extracted threetimes with ethyl acetate. The combined organic phases weredried with MgSO4 and concentrated in vacuo. The residue waspurified by column chromatography on silica gel.

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259
[2]Beilstein Journal of Organic Chemistry,2018,vol. 14,p. 734 - 746

10
[ 7218-22-6 ]
[ 57295-30-4 ]

Reference： [1]Monatshefte fur Chemie,1964,vol. 95,p. 129 - 146

11
[ 141-82-2 ]
[ 57295-30-4 ]
[ 90843-49-5 ]

Reference： [1]Monatshefte fur Chemie,1964,vol. 95,p. 116 - 128

12
[ 74-90-8 ]
[ 57295-30-4 ]
(R)-3-hydroxy-4-methylbenzaldehyde cyanohydrin [ No CAS ]

Reference： [1]Journal of Organic Chemistry,1997,vol. 62,p. 3867 - 3873

13
[ 57295-30-4 ]
[ 107-30-2 ]
3-(methoxymethoxy)-4-methylbenzaldehyde [ No CAS ]

Reference： [1]Journal of Organic Chemistry,1997,vol. 62,p. 3867 - 3873

15
[ 50-00-0 ]
[ 90953-62-1 ]
[ 154550-07-9 ]
[ 57295-30-4 ]

Reference： [1]Synthetic Communications,2005,vol. 35,p. 2869 - 2874

16
[ 6940-78-9 ]
[ 57295-30-4 ]
3-(4-chloro-butoxy)-4-methyl-benzaldehyde [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

17
[ 41838-46-4 ]
[ 57295-30-4 ]
[ 359879-55-3 ]

Yield	Reaction Conditions	Operation in experiment
50%	With sodium cyanoborohydride; acetic acid; In methanol; at 0℃; for 3h;	4-Amino-1-methylpiperidine (57MBT36B) (26 mg, 0.231 mmol) was dissolved in methanol (1 mL) and <strong>[57295-30-4]3-hydroxy-4-methylbenzaldehyde</strong> (32 mg, 0.231 mmol) and acetic acid (33 muL) were added. The mixture was cooled to 0 C. NaBH3CN (29 mg, 0.462 mmol) was added and the cooling bath was removed. After 3 h the reaction mixture was evaporated and flash chromatography (0-30% MeOH in CH2Cl2) gave 27 mg (50%) of N-((3-hydroxy-4-methylphenyl)methyl)-4-amino-1-methylpiperidine (57MBT44C) as a white solid. Rf=0.27 (10% MeOH in CH2Cl2+3.5% NH4OH). HPLC-MS (method A) showed MH+=235. UV/MS (%)=99/99.
50%	With sodium cyanoborohydride; acetic acid; In methanol; at 0℃; for 3h;	4-Amino-l-methylpiperidine (57MBT36B) (26 mg, 0.231 mmol) was dissolved in methanol (1 mL) and <strong>[57295-30-4]3-hydroxy-4-methylbenzaldehyde</strong> (32 mg, 0.231 mmol) and acetic acid (33muL) were added. The mixture was cooled to 0 C. NaBH3 CN (29 mg, 0.462 mmol) was added and the cooling bath was removed. After 3 h the reaction mixture was evaporated and flash chromatography (0-30% MeOH in CH2Cl2) gave 27 mg (50%) of N-((3-hydroxy-4-methylphenyl)methyl)-4-amino-l-methylpiperidine (57MBT44C) as a white solid. Rf =0.27 (10% MeOH in CH2Cl2 +3.5% NH4 OH). HPLC-MS (method A) showed MH+ =235. UV/MS(%)=99/99.

Reference： [1]Patent: US2015/259291,2015,A1 .Location in patent: Paragraph 0599
[2]Patent: WO2007/124136,2007,A1 .Location in patent: Page/Page column 127

18
[ 57295-30-4 ]
[ 919088-12-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

19
[ 57295-30-4 ]
2-{4-methyl-3-[4-(4-methyl-piperazin-1-yl)-butoxy]-phenyl}-1H-benzoimidazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

20
[ 57295-30-4 ]
5-methyl-2-{4-methyl-3-[4-(4-methyl-piperazin-1-yl)-butoxy]-phenyl}-1H-benzoimidazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

21
[ 57295-30-4 ]
5-chloro-2-{4-methyl-3-[4-(4-methyl-piperazin-1-yl)-butoxy]-phenyl}-1H-benzoimidazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

22
[ 57295-30-4 ]
5-chloro-6-fluoro-2-{4-methyl-3-[4-(4-methyl-piperazin-1-yl)-butoxy]-phenyl}-1H-benzoimidazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 6043 - 6048

23
[ 586-30-1 ]
[ 57295-30-4 ]

Reference： [1]Synthetic Communications,2005,vol. 35,p. 2869 - 2874
[2]Patent: US2011/136801,2011,A1

24
[ 57295-30-4 ]
(R)-Hydroxy-(3-methoxymethoxy-4-methyl-phenyl)-acetonitrile [ No CAS ]

Reference： [1]Journal of Organic Chemistry,1997,vol. 62,p. 3867 - 3873

25
[ 57295-30-4 ]
(E)-3-Methoxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

26
[ 57295-30-4 ]
(E)-3-Ethoxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

27
[ 57295-30-4 ]
(E)-3-Benzoyloxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

28
[ 57295-30-4 ]
(E)-3-Hexyloxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

29
[ 57295-30-4 ]
(E)-3-Dodecyloxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

30
[ 57295-30-4 ]
(E)-3-Hexadecyloxy-4-methyl-N-phenylbenzaldimin [ No CAS ]

Reference： [1]Journal fur Praktische Chemie - Chemiker-Zeitung,1994,vol. 336,p. 255 - 259

31
[ 104-87-0 ]
KOH [ No CAS ]
[ 57295-30-4 ]

Reference： [1]Liebigs Annalen der Chemie,1985,vol. 1985,p. 1413 - 1421

32
[ 57295-30-4 ]
[ 4685-50-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

33
[ 57295-30-4 ]
[ 57335-02-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

34
[ 57295-30-4 ]
[ 64829-31-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

35
[ 57295-30-4 ]
[ 3188-31-6 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

36
[ 57295-30-4 ]
[ 75097-32-4 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

37
[ 57295-30-4 ]
[ 75156-81-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

38
[ 57295-30-4 ]
[ 75156-82-0 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

39
[ 57295-30-4 ]
[ 75156-89-7 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

40
[ 57295-30-4 ]
[ 75156-93-3 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

41
[ 57295-30-4 ]
methyl α-<3-acetoxy-4-(N-ethoxycarbonyl-N-methylamino)-pyrrolidin-2-ylidene>-α-(2-bromo-5-methoxy-4-methylphenyl)-acetate [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

42
[ 57295-30-4 ]
[ 75156-90-0 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

43
[ 57295-30-4 ]
[ 75156-86-4 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

44
[ 57295-30-4 ]
[ 75156-91-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 1607 - 1613

45
[ 57295-30-4 ]
[ 91061-48-2 ]

Reference： [1]Monatshefte fur Chemie,1964,vol. 95,p. 116 - 128

46
[ 7577-74-4 ]
[ 57295-30-4 ]

Reference： [1]Monatshefte fur Chemie,1963,vol. 94,p. 1262 - 1270

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 61 N-(1-trans-(2-(4-methyl-3-phenoxyphenyl)cyclopropyl)methyl)-N-hydroxyurea To a solution of 3-hydroxy-4-methylbenzoic acid (15.22 g, 0.1 mole) in THF (250 mL) was added borane.dimethylsulfide (32.0 mL of a 10.0 M solution, 0.32 mole) dropwise. Upon completion of addition, the reaction was stirred for 18 hrs. It was then quenched dropwise by the slow addition of aqueous 10% HCl (250 mL) and extracted with ethylacetate (3*250 mL). The organics were combined, dried with MgSO4 and concentrated. The resulting residue was taken up in CH2 Cl2 (500 mL) and pyridinium dichromate (45.15 g, 0.12 mole) was added. The resulting mixture was stirred for 48 hrs. It was then filtered through Celite and concentrated. The resulting residue was chromatographed (silica gel, ether:hexanes, 30:70) to afford 4.55 g of 3-hydroxy-4-methylbenzaldehyde as a yellow solid.
		EXAMPLE 61 N-(1-trans-(2-(4-methyl-3-phenoxyphenyl)cyclopropyl)methyl)-N-hydroxyurea To a solution of 3-hydroxy-4-methylbenzoic acid (15.22 g, 0.1 mole) in THF (250 mL) was added borane.dimethylsulfide (32.0 mL of a 10.0M solution, 0.32 mole) dropwise. Upon completion of addition, the reaction was stirred for 18 hrs. It was then quenched dropwise by the slow addition of aqueous 10% HCl (250 mL) and extracted with ethylacetate (3*250 mL). The organics were combined, dried with MgSO4 and concentrated. The resulting residue was taken up in CH2 Cl2 (500 mL) and pyridinium dichromate (45.15 g, 0.12 mole) was added. The resulting mixture was stirred for 48 hrs. It was then filtered through Celite and concentrated. The resulting residue was chromatographed (silica gel, ether:hexanes, 30:70) to afford 4.55 g of 3-hydroxy-4-methylbenzaldehyde as a yellow solid.

48
[ 57295-30-4 ]
[ 883978-28-7 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium tert-butylate; In tetrahydrofuran; at 0 - 20℃; for 2h;	Under an atmosphere of Argon, to a solution of n-hexylphosphonium bromide (1.07 g) in tetrahydrofuran (10 mL) was added potassium t-butoxide (336 mg) at room temperature and the solution was stirred for 30 minutes. After cooling in ice bath, <strong>[57295-30-4]3-hydroxy-4-methylbenzaldehyde</strong> (136 mg) was added to the reaction solution, which was stirred at room temperature for 1.5 hours. The reaction solution was diluted with t-butyl methyl ether. The solution was washed with dilute hydrochloric acid, water and brine, dried over anhydrous sodium sulfate and concentrated. The obtained residue was purified by column chromatography on silica gel (ethyl acetate : hexane = 1 : 4) to give the title compound (180 mg) having the following physical data. TLC:Rf 0.63 (ethyl acetate : hexane = 1 : 4).

Reference： [1]Patent: EP1806148,2007,A1 .Location in patent: Page/Page column 20

49
[ 57295-30-4 ]
[ 105-36-2 ]
[ 1310697-12-1 ]

Yield	Reaction Conditions	Operation in experiment
97%	With potassium carbonate; In N,N-dimethyl-formamide; at 60℃; for 3h;	To a solution of the product step (ii) (43.6 mg, 0.32 mmol) in DMF (0.5 ml) ethylbromoacetate (37.3 ul, 0.336 mmol) and K2CO3 (46.4 mg, 0.336 mmol) was added at rt. After stirring for 3 h at 60 C., diluted with AcOEt and H2O was added. The aq. layer was extracted with AcOEt, dried over Na2SO4, and concentrated. The residue was purified by flash column chromatography to give the title compound (68.9 mg, 97%) as colorless oil.1H NMR delta (CDCl3) 9.91 (1H, s), 7.41 (1H, dd, J=7.52, 1.32 Hz), 7.34 (1H, d, J=7.56 Hz), 7.22 (1H, m), 4.72 (2H, s), 4.28 (2H, q, J=7.16 Hz), 2.38 (3H, s), 1.31 (3H, t, J=7.12 Hz).

Reference： [1]Patent: US2011/136801,2011,A1 .Location in patent: Page/Page column 44

50
[ 90953-62-1 ]
[ 57295-30-4 ]

Yield	Reaction Conditions	Operation in experiment
11%	With manganese(IV) oxide; In tetrahydrofuran; at 20 - 50℃; for 6h;	To a solution of the product step (i) (440.0 mg, 3.18 mmol) in THF (4.4 mL) MnO2 (552.9 mg, 6.36 mmol) was added at rt. After stirring for 6 h at 50 C., the mixture was filtered through the celite pad. The filtrate was concentrated, and the residue was purified by flash column chromatography to give the title compound (46.1 mg, 11%) as a pale yellow solid.1H NMR delta (CDCl3) 9.90 (1H, s), 7.36 (1H, dd, J=7.76, 1.44 Hz), 7.30 (1H, s), 7.29 (1H, d, J=5.52 Hz), 5.33 (1H, s), 2.33 (3H, s).

Reference： [1]Patent: US2011/136801,2011,A1 .Location in patent: Page/Page column 44

51
[ 4433-85-6 ]
[ 57295-30-4 ]
[ 57-13-6 ]
[ 1264939-33-4 ]

Reference： [1]Asian Journal of Chemistry,2011,vol. 23,p. 1713 - 1715

52
[ 57295-30-4 ]
[ 1264939-40-3 ]

Reference： [1]Asian Journal of Chemistry,2011,vol. 23,p. 1713 - 1715

53
[ 57295-30-4 ]
C₂₂H₂₀N₂O₃ [ No CAS ]

Reference： [1]Asian Journal of Chemistry,2011,vol. 23,p. 1713 - 1715

54
[ 57295-30-4 ]
C₁₅H₁₄N₄O₂S₂ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

55
[ 57295-30-4 ]
C₁₅H₁₄N₄O₂S₂ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

56
[ 57295-30-4 ]
C₁₅H₁₄N₄O₄S₂ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

57
[ 57295-30-4 ]
[ 945001-78-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

58
[ 57295-30-4 ]
C₁₃H₁₀ClN₃OS [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

59
[ 57295-30-4 ]
[ 14527-26-5 ]
[ 105-56-6 ]
C₁₃H₁₁N₃O₂S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 747 - 752

60
[ 3731-51-9 ]
[ 57295-30-4 ]
[ 68-11-1 ]
[ 1600490-07-0 ]

Yield	Reaction Conditions	Operation in experiment
82%		General procedure: Benzylamine (1.0 mmol) was added to a stirred solution of benzaldehyde (1.2 mmol) in dichloromethane (10 mL) at 0 C. After stirring for 5 min thioglycolic acid (2.0 mmol) wasadded to the above reaction and stirring was continued for another 5 min at 0 C. Silica gel (0.5g) was then added and the mixture was stirred for 4 h at room temperature when TLC showedcomplete conversion of amine. The solvent was removed under reduced pressure and the slurryso formed was purified by flash column chromatography over 12 g SNAP cartridge by elutingwith gradient of 10-20% ethyl acetate in hexane to afford 3-benzyl-2-phenylthiazolidin-4-one in 87% yield.

Reference： [1]Tetrahedron Letters,2014,vol. 55,p. 2463 - 2466

61
[ 57295-30-4 ]
4-(5-(2,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)benzohydrazide [ No CAS ]
4-(5-(2,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)-N'-(3-hydroxy-4-methylbenzylidene)benzohydrazide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70.1%	With acetic acid; In methanol; for 3h;Reflux;	General procedure: Equimolar quantities (1 mmol) of compound 5 and substituted benzaldehydes (1 mmol) in methanol (25 mL) were refluxed for 3 h, in the presence of catalytic amount of glacial acetic acid. The resulting solid was filtered and recrystallized from methanol in good yields.

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 4155 - 4162

62
[ 57295-30-4 ]
[ 701-27-9 ]
3-(m-fluorobenzenesulfonyloxy)-4-methylbenzaldehyde [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
44.2%	With triethylamine; In dichloromethane; at 0 - 20℃; for 8.5h;	Compound A (see Document Liebigs Annalender Chemie, 1985, (7), 1413-21 prepared) 1.36g (10mmol) with 30mlCH2Cl2 in 100ml round bottom flask, at 0 deg. C was slowly added 1.21g (12mmol) of triethylamine, after stirring for 30min, at the same conditions was slowly added dropwise at between 0 deg. C fluorobenzenesulfonyl chloride 2.13g (11mmol), after the addition is complete, slowly warm to room temperature, the reaction 8h, followed by addition of 200ml of ice water the reaction liquid dispersion, CH2Cl2 layer was collected, washed three times with saturated brine, the organic phase was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product E, the above crude product with 20ml of ethyl acetate recrystallization purified product B 1.3g (yield: 44.2%).

Reference： [1]Patent: CN105481850,2016,A .Location in patent: Paragraph 0540; 0541; 0542

63
[ 57295-30-4 ]
[ 126-81-8 ]
C₂₄H₂₉NO₃ [ No CAS ]

Reference： [1]Applied Organometallic Chemistry,2018,vol. 32

64
[ 57295-30-4 ]
[ 111373-03-6 ]
2-{4-[(3-hydroxy-4-methylphenyl)methyl]piperazin-1-yl}benzonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
98%		<strong>[57295-30-4]3-Hydroxy-4-methylbenzaldehyd</strong>e (204.2 mg, 1.500 mmol) and 2-(piperazin-1- yl)benzonitrile [Amine 72] (294.9 mg, 1.575 mmol) were dissolved in DCM (12 ml) and stirred at room temperature for 30 mi NaBH(OAc)3 (636 mg, 3.0 mmol) was then added and the mixture stirred for 18 hours. The reaction mixture was stirred with water (10 ml) and NaHCO3 added until pH 8.4 was achieved then the aqueous was extracted with DCM (2 x 10 ml). The organic layer was dried (MgSO4) and concentrated in vacuo to yield the title compound as a cream solid (531 mg, 98%).1H NIVIR (500 IVIFIz, Chloroform-d) 7.48 (dd, J = 7.9, 1.6 Hz, 1H), 7.42 - 7.37 (m, 1H), 6.99 (d, J = 7.5 Hz, 1H), 6.92 (dd, J = 7.7, 6.0 Hz, 2H), 6.81 -6.68 (m, 2H), 3.45 (s, 2H), 3.20-3.15 (m, 4H), 2.65-2.52 (m, 4H), 2.16 (s, 3H).LCMS Method 2 - Tr = 0.85 mm (ES+) (M+H) 308

Reference： [1]Patent: WO2018/89433,2018,A1 .Location in patent: Paragraph 00358

65
[ 57295-30-4 ]
[ 111373-03-6 ]
2-[4-(5-[4-(2-cyanophenyl)piperazin-1-yl]methyl}-2-methylphenoxy)piperidin-1-yl]benzonitrile [ No CAS ]

Reference： [1]Patent: WO2018/89433,2018,A1

66
[ 57295-30-4 ]
(E)-2-((4-(3-(3-hydroxy-4-methylphenyl)acryloyl)phenyl)amino)-N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

67
[ 57295-30-4 ]
(E)-2-((4-(3-(3-hydroxy-4-methylphenyl)acryloyl)phenyl)amino)-N-(4-sulfamoyl phenyl)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

68
[ 57295-30-4 ]
(E)-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)-2-((4-(3-(3-hydroxy-4-methylphenyl)acryloyl)phenyl)amino)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

69
[ 57295-30-4 ]
(E)-N-(4-(N-acetylsulfamoyl)phenyl)-2-((4-(3-(3-hydroxy-4-methylphenyl)acryloyl) phenyl)amino)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

70
[ 57295-30-4 ]
(E)-2-((4-(3-(3-hydroxy-4-methylphenyl)acryloyl)phenyl)amino)-N-(4-(N-(pyrimidin-2-yl) sulfamoyl) phenyl)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

71
[ 57295-30-4 ]
(E)-N-(4-(N-(6-chloropyridazin-3-yl)sulfamoyl)phenyl)-2-((4-(3-(3-hydroxy-4-methoxyphenyl) acryloyl)phenyl)amino)acetamide [ No CAS ]

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

72
[ 57295-30-4 ]
[ 99-92-3 ]
C₁₆H₁₅NO₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In methanol; at 20℃;	General procedure: The synthesis of chalcone derivatives [I] was conductedaccording to the procedure reported in the reference byClaisen-Schmidt condensation reaction.10-12 Acetophenonederivative (2.5 mmol) and substituted benzaldehydes (2.5mmol) were dissolved in 30 ml methanol. To the solution,10 ml NaOH (20%) solution was added dropwise and thereaction mixture was stirred for 1-2 hour at room temperatureby a magnetic stirrer and kept for overnight. Subsequently,it was poured into ice water and neutralized.The solid precipitates were filtered off and recrystallizedfrom methanol or ethyl acetate.

Reference： [1]Journal of the Korean Chemical Society,2018,vol. 62,p. 377 - 385

73
[ 57295-30-4 ]
1-cyclopenta-1,3-dienyl-5-[2-(3-hydroxy-4-methylphenyl)-3-(2-methylcyclobutylmethyl)-4-oxoazetidine]pyrazole-3-carboxylic acid ethyl ester [ No CAS ]

Reference： [1]Patent: CN108658942,2018,A

74
[ 57295-30-4 ]
1-cyclopenta-1,3-dienyl-5-[(2-(3-hydroxy-4-methylphenyl)-3-(2-methylcyclobutylmethyl)-4-oxoazetidine)]pyrazole-3-carbonitrile [ No CAS ]

Reference： [1]Patent: CN108658942,2018,A

75
[ 57295-30-4 ]
5-amino-1-cyclopenta-1,3-dienyl-1H-pyrazole-3-carbonitrile [ No CAS ]
1-cyclopenta-1,3-dienyl-5-[(3-hydroxy-4-methylbenzylidene)amino]pyrazole-3-carbonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With toluene-4-sulfonic acid; In toluene; at 120℃; for 0.333333h;Molecular sieve; Microwave irradiation; Sealed tube;	The collected 5mmol of Butyl 5-amino-1-(3-hydroxyphenyl)-1H-pyrazole-3-carbonitrile and 5 mmol of <strong>[57295-30-4]3-Hydroxy-4-methyl-benzaldehyd</strong>e, 0.1 g of p-toluenesulfonic acid, 4 A of molecular sieve 1 g and 30 mL of solvent toluene were added to the polytetrafluoroethylene liner for microwave hydrothermal apparatus, and the reaction kettle was sealed. It was placed in a microwave hydrothermal apparatus, microwave power was 300 W, heated to 120 C, and reacted for 20 min. After the reaction was completed, suction filtration was carried out, and the filtrate was collected. 3 g of silica gel powder was added to the filtrate to spin dried into a powder, and then subjected silica gel column chromatography separation (dry method, V ethyl acetate: V petroleum ether =1: 10) to obtain 1-cyclopenta-1,3-dienyl-5-[(3-hydroxy-4-methyl-benzylidene)amino]pyrazole-3-carbonitrile.

Reference： [1]Patent: CN108658942,2018,A .Location in patent: Paragraph 0092-0096

76
[ 24973-22-6 ]
[ 57295-30-4 ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 6063 - 6082

77
[ 57295-30-4 ]
[ 67-64-1 ]
(E)-4-(3-hydroxy-4-methylphenyl)but-3-en-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 6063 - 6082

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 57295-30-4 ]

Aryls

[ 698-27-1 ]

2-Hydroxy-4-methylbenzaldehyde

Similarity: 0.97

[ 15174-69-3 ]

4-Hydroxy-3-methylbenzaldehyde

Similarity: 0.97

[ 487-69-4 ]

2,4-Dihydroxy-6-methylbenzaldehyde

Similarity: 0.95

[ 613-84-3 ]

2-Hydroxy-5-methylbenzaldehyde

Similarity: 0.94

[ 2233-18-3 ]

4-Hydroxy-3,5-dimethylbenzaldehyde

Similarity: 0.94

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 57295-30-4 ] {[proInfo.proName]}

Quality Control of [ 57295-30-4 ]

Related Doc. of [ 57295-30-4 ]

Product Details of [ 57295-30-4 ]

Calculated chemistry of [ 57295-30-4 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 57295-30-4 ]

Application In Synthesis of [ 57295-30-4 ]

[ 57295-30-4 ] Synthesis Path-Upstream 1~10

[ 57295-30-4 ] Synthesis Path-Downstream 1~77

Related Functional Groups of [ 57295-30-4 ]

Aryls

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 57295-30-4 ]